ATRA Atara Biotherapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ATRA

Price (delayed)

$2.945

Market cap

$282.5M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.24

Enterprise value

$277.72M

Atara Biotherapeutics, Inc.(@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers ...

Highlights
The EPS has increased by 38% YoY and by 9% from the previous quarter
The net income has increased by 33% YoY and by 8% from the previous quarter
The equity has dropped by 55% year-on-year and by 32% since the previous quarter
The debt has increased by 45% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.atarabio.com
Peers: AGEN IMGN

Key stats

What are the main financial stats of ATRA
Market
Shares outstanding
95.93M
Market cap
$282.5M
Enterprise value
$277.72M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.21
Price to sales (P/S)
4.72
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.37
Earnings
Revenue
$63.57M
EBIT
-$230.28M
EBITDA
-$215.71M
Free cash flow
-$179.86M
Per share
EPS
-$2.24
Free cash flow per share
-$1.76
Book value per share
$1.33
Revenue per share
$0.62
TBVPS
$3.69
Balance sheet
Total assets
$376.42M
Total liabilities
$249.78M
Debt
$88.3M
Equity
$126.64M
Working capital
$216.16M
Liquidity
Debt to equity
0.7
Current ratio
3.74
Quick ratio
3.59
Net debt/EBITDA
0.02
Margins
EBITDA margin
-339.3%
Gross margin
100%
Net margin
-359.1%
Operating margin
-441.2%
Efficiency
Return on assets
-57.9%
Return on equity
-114.8%
Return on invested capital
-79.6%
Return on capital employed
-77.4%
Return on sales
-362.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ATRA stock price

How has the Atara Biotherapeutics stock price performed over time
Intraday
-2.48%
1 week
-4.38%
1 month
-30.38%
1 year
-70.01%
YTD
-10.21%
QTD
-10.21%

Financial performance

How have Atara Biotherapeutics's revenue and profit performed over time
Revenue
$63.57M
Gross profit
$63.57M
Operating income
-$280.51M
Net income
-$228.3M
Gross margin
100%
Net margin
-359.1%
The net margin has soared by 79% YoY but it has decreased by 3% from the previous quarter
ATRA's operating margin has surged by 74% year-on-year but it is down by 4.8% since the previous quarter
The net income has increased by 33% YoY and by 8% from the previous quarter
The operating income has grown by 18% YoY and by 6% from the previous quarter

Growth

What is Atara Biotherapeutics's growth rate over time

Valuation

What is Atara Biotherapeutics stock price valuation
P/E
N/A
P/B
2.21
P/S
4.72
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.37
The EPS has increased by 38% YoY and by 9% from the previous quarter
The equity has dropped by 55% year-on-year and by 32% since the previous quarter
The price to book (P/B) is 35% lower than the 5-year quarterly average of 3.5 and 19% lower than the last 4 quarters average of 2.8
ATRA's P/S is 68% below its last 4 quarters average of 15.1
Atara Biotherapeutics's revenue has decreased by 10% QoQ

Efficiency

How efficient is Atara Biotherapeutics business performance
The ROS has soared by 78% YoY but it has decreased by 3.5% from the previous quarter
Atara Biotherapeutics's return on invested capital has increased by 35% YoY and by 8% QoQ
The company's return on assets rose by 19% YoY and by 2.2% QoQ
The company's return on equity fell by 11% YoY and by 10% QoQ

Dividends

What is ATRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ATRA.

Financial health

How did Atara Biotherapeutics financials performed over time
The total assets is 51% more than the total liabilities
ATRA's total liabilities is up by 38% since the previous quarter and by 33% year-on-year
The total assets has contracted by 20% YoY but it has grown by 2.2% from the previous quarter
The debt is 30% less than the equity
ATRA's debt to equity has surged by 112% since the previous quarter
The equity has dropped by 55% year-on-year and by 32% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.